A Drag-Delivery Vehicle Combining the Targeting and Thermal Ablation of HER2 + Breast-Cancer Cells with Triggered Drug Release

摘要

Breast cancer is the second leading cause of cancer-related deaths in women, surpassed only by lung cancer.Current clinical therapies target the estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) to reduce cancer-cell proliferation. These methods are often used in conjunction with surgery, chemotherapy, and/or radiation in efforts to eradicate the disease. However, 25% of patients face tumor recurrence and resistance within 5 years after treatment. Ideally, the initial treatment would supply a robust, broad-spectrum therapy to eliminate all cancer cells while minimizing damage to healthy tissue.